Does DENTSPLY SIRONA Inc. (XRAY) offer a good opportunity for investors?

DENTSPLY SIRONA Inc. (NASDAQ: XRAY) stock fell -0.59% on Thursday to $36.91 against a previous-day closing price of $37.13. With 1.44 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.96 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $37.07 whereas the lowest price it dropped to was $36.42. The 52-week range on XRAY shows that it touched its highest point at $43.24 and its lowest point at $26.48 during that stretch. It currently has a 1-year price target of $44.70. With its current market cap of 7.90 billion, XRAY has annualized dividend of $0.56 while the current yield stands at 1.52%. Beta for the stock currently stands at 0.93.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XRAY was down-trending over the past week, with a drop of -8.86%, but this was down by -9.82% over a month. Three-month performance surged to 7.52% while six-month performance rose 21.53%. The stock lost -3.12% in the past year, while it has gained 15.92% so far this year. A look at the trailing 12-month EPS for XRAY yields -4.83 with Next year EPS estimates of 2.28. For the next quarter, that number is 0.43. This implies an EPS growth rate of -336.20% for this year and 18.41% for next year. EPS is expected to grow by 3.90% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 7.90%.

Float and Shares Shorts:

At present, 214.50 million XRAY shares are outstanding with a float of 211.19 million shares on hand for trading. On Apr 27, 2023, short shares totaled 7.38 million, which was 3.47% higher than short shares on Mar 30, 2023. In addition to Mr. Simon D. Campion as the firm’s CEO, Pres & Director, Mr. Glenn G. Coleman serves as its Exec. VP & CFO.

Institutional Ownership:

Through their ownership of 106.83% of XRAY’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 61.49% of XRAY, in contrast to 41.06% held by mutual funds. Shares owned by individuals account for 1.96%. As the largest shareholder in XRAY with 11.34% of the stake, The Vanguard Group, Inc. holds 24,415,518 shares worth 24,415,518. A second-largest stockholder of XRAY, Artisan Partners LP, holds 13,732,196 shares, controlling over 6.38% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in XRAY, holding 11,020,582 shares or 5.12% stake. With a 3.20% stake in XRAY, the First Eagle Global Fund is the largest stakeholder. A total of 6,900,950 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 3.10% of XRAY stock, is the second-largest Mutual Fund holder. It holds 6,681,828 shares valued at 280.17 million. Nuance Mid Cap Value Fund holds 2.83% of the stake in XRAY, owning 6,088,169 shares worth 255.28 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, XRAY reported revenue of $1.02B and operating income of $126.00M. The EBITDA in the recently reported quarter was $197.00M and diluted EPS was $0.34.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for XRAY since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With XRAY analysts setting a high price target of $51.00 and a low target of $40.00, the average target price over the next 12 months is $44.27. Based on these targets, XRAY could surge 38.17% to reach the target high and rise by 8.37% to reach the target low. Reaching the average price target will result in a growth of 19.94% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Dividends & Yield:

In terms of dividends, XRAY has a current ratio of $0.56, which is $0.56 over the trailing 12-months, while a dividend of $0.41 is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and XRAY currently yields $1.4. In the past year, XRAY’s dividend yield has been $1.4, but when looking at the stock over the past five years, its yield has been $0.91. Accordingly, XRAY has a current buyback yield of $3.24. This was $3.24 for the TTM, and it was $2.68 for the past five years.

Summary of Insider Activity:

Insiders traded XRAY stock several times over the past three months with 29 Buys and 5 Sells. In these transactions, 143,638 shares were bought while 13,541 shares were sold. The number of buy transactions has increased to 93 while that of sell transactions has risen to 15 over the past year. The total number of shares bought during that period was 1,187,324 while 127,035 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *